Ypsomed Holding Valuation
Is 0QLQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0QLQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0QLQ (CHF388) is trading below our estimate of fair value (CHF486.28)
Significantly Below Fair Value: 0QLQ is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0QLQ?
Other financial metrics that can be useful for relative valuation.
| What is 0QLQ's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CHF 5.29b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 10x |
| Enterprise Value/EBITDA | 41.2x |
| PEG Ratio | 2x |
Price to Earnings Ratio vs Peers
How does 0QLQ's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 37.4x | ||
CTEC ConvaTec Group | 37.3x | 21.0% | UK£4.4b |
AMS Advanced Medical Solutions Group | 45.6x | 23.0% | UK£507.4m |
TSTL Tristel | 30.8x | 17.5% | UK£200.1m |
SN. Smith & Nephew | 35.9x | 22.6% | UK£8.4b |
0QLQ Ypsomed Holding | 67.5x | 33.3% | CHF 5.3b |
Price-To-Earnings vs Peers: 0QLQ is expensive based on its Price-To-Earnings Ratio (67.5x) compared to the peer average (37.4x).
Price to Earnings Ratio vs Industry
How does 0QLQ's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: 0QLQ is expensive based on its Price-To-Earnings Ratio (67.5x) compared to the European Medical Equipment industry average (30.5x).
Price to Earnings Ratio vs Fair Ratio
What is 0QLQ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 67.5x |
| Fair PE Ratio | 49.8x |
Price-To-Earnings vs Fair Ratio: 0QLQ is expensive based on its Price-To-Earnings Ratio (67.5x) compared to the estimated Fair Price-To-Earnings Ratio (49.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CHF 388.00 | CHF 426.20 +9.8% | 13.0% | CHF 495.00 | CHF 326.00 | n/a | 5 |
| Oct ’25 | CHF 414.38 | CHF 426.20 +2.9% | 13.0% | CHF 495.00 | CHF 326.00 | n/a | 5 |
| Sep ’25 | CHF 415.03 | CHF 426.20 +2.7% | 13.0% | CHF 495.00 | CHF 326.00 | n/a | 5 |
| Aug ’25 | CHF 400.50 | CHF 378.00 -5.6% | 13.8% | CHF 430.00 | CHF 326.00 | n/a | 2 |
| Jul ’25 | CHF 412.50 | CHF 378.00 -8.4% | 13.8% | CHF 430.00 | CHF 326.00 | n/a | 2 |
| Jun ’25 | CHF 381.21 | CHF 362.00 -5.0% | 13.3% | CHF 430.00 | CHF 326.00 | n/a | 3 |
| May ’25 | CHF 329.00 | CHF 351.33 +6.8% | 9.8% | CHF 400.00 | CHF 324.00 | n/a | 3 |
| Nov ’24 | CHF 250.50 | CHF 320.00 +27.7% | 3.1% | CHF 330.00 | CHF 310.00 | CHF 388.00 | 2 |
| Oct ’24 | CHF 269.50 | CHF 315.00 +16.9% | 4.8% | CHF 330.00 | CHF 300.00 | CHF 414.38 | 2 |
| Sep ’24 | CHF 250.00 | CHF 288.33 +15.3% | 4.6% | CHF 300.00 | CHF 270.00 | CHF 415.03 | 3 |
| Aug ’24 | CHF 256.00 | CHF 288.33 +12.6% | 4.6% | CHF 300.00 | CHF 270.00 | CHF 400.50 | 3 |
| Jul ’24 | CHF 269.83 | CHF 288.33 +6.9% | 4.6% | CHF 300.00 | CHF 270.00 | CHF 412.50 | 3 |
| Jun ’24 | CHF 248.50 | CHF 276.67 +11.3% | 6.1% | CHF 300.00 | CHF 260.00 | CHF 381.21 | 3 |
| May ’24 | CHF 208.99 | CHF 226.67 +8.5% | 6.8% | CHF 240.00 | CHF 205.00 | CHF 329.00 | 3 |
| Apr ’24 | CHF 191.57 | CHF 223.33 +16.6% | 5.9% | CHF 235.00 | CHF 205.00 | CHF 358.46 | 3 |
| Mar ’24 | CHF 183.02 | CHF 223.33 +22.0% | 5.9% | CHF 235.00 | CHF 205.00 | CHF 365.00 | 3 |
| Feb ’24 | CHF 185.89 | CHF 223.33 +20.1% | 5.9% | CHF 235.00 | CHF 205.00 | CHF 304.05 | 3 |
| Jan ’24 | CHF 169.01 | CHF 200.00 +18.3% | 13.4% | CHF 230.00 | CHF 165.00 | CHF 304.00 | 3 |
| Dec ’23 | CHF 198.80 | CHF 206.67 +4.0% | 14.3% | CHF 230.00 | CHF 165.00 | CHF 304.00 | 3 |
| Nov ’23 | CHF 160.83 | CHF 191.67 +19.2% | 11.7% | CHF 220.00 | CHF 165.00 | CHF 250.50 | 3 |
Analyst Forecast: Target price is less than 20% higher than the current share price.